BioGiox and Labnovation Showcase Molecular Diagnostics and HbA1c Testing at MEDICA 2026

By LabMedica International staff writers
Posted on 16 Nov 2026

BioGiox and Labnovation showcase a range of diagnostic technologies at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany. The companies highlight solutions for high-performance liquid chromatography (HPLC), thalassemia screening, molecular diagnostics, and point-of-care testing (POCT), alongside new immunoassays for Alzheimer's disease-related biomarkers.

Among the featured technologies are HPLC-based testing solutions for glycated hemoglobin (HbA1c) measurement and thalassemia screening. Labnovation's portfolio includes the LD-560 and LD-600 fully automated HbA1c analyzers, which use HPLC technology to quantify glycated hemoglobin. The systems offer testing speeds of approximately 90 and 65 seconds per sample, respectively, with automated sample loading capabilities.


Image: At Hall 1, E43, BioGiox and Labnovation are showcasing our comprehensive portfolio of cutting-edge diagnostic solutions (Photo courtesy of BioGiox)

The LD-560 and LD-600 also support hemoglobin variant analysis, including the detection of HbS, HbC, HbD, and HbE. Their testing capabilities extend to the measurement of HbA2 and HbF, which are relevant to thalassemia screening and the evaluation of hemoglobin disorders. These functions enable laboratories to perform diabetes monitoring and hemoglobin analysis using a single instrument platform.

For decentralized testing, the companies highlight point-of-care HbA1c and molecular diagnostic solutions. Labnovation's LD-100 HbA1c analyzer uses the boronate affinity method to measure glycated hemoglobin in whole blood or fingertip blood samples. The compact instrument delivers results in under three minutes and is designed for use in clinical laboratories, hospitals, and outpatient settings.

The molecular diagnostics portfolio includes automated technologies for nucleic acid extraction and PCR preparation. BioGiox's BG-Star-96 workstation integrates sample processing, nucleic acid extraction, and PCR reaction preparation into a single automated workflow. The system completes extraction and PCR preparation in approximately 40 minutes and supports simultaneous preparation of six different PCR assays.

The company also offers rapid molecular testing platforms, including the Flix disc CH-0104 fully automated nucleic acid analyzer. The cartridge-based system integrates nucleic acid extraction and amplification, supporting detection of up to 16 targets in approximately 30–45 minutes. Its enclosed design and modular configuration, expandable to eight modules, are intended to support decentralized infectious disease testing.

Another highlight is BioGiox's new portfolio of immunoassays targeting biomarkers associated with Alzheimer's disease and neurodegeneration. The assays include phosphorylated tau 217 (p-Tau217), phosphorylated tau 181 (p-Tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid-beta 1-40 and 1-42. These blood-based biomarkers are being investigated for their role in disease assessment and monitoring.

The Alzheimer's-related assays are designed for automated chemiluminescence immunoassay platforms, supporting laboratory analysis of multiple biomarkers involved in amyloid pathology, tau pathology, and neurodegeneration. According to BioGiox, its testing platform can deliver initial results in approximately 20 minutes, with throughput of up to 200 tests per hour, depending on the assay and instrument configuration.

BioGiox and Labnovation exhibit at Booth E43 in Hall 1, where visitors can explore their diagnostic technologies and discuss potential collaborations. Their participation highlights applications ranging from routine diabetes monitoring and molecular infectious disease testing to emerging blood-based biomarker assays for neurodegenerative diseases.


Latest Medica 2026 News